Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
KURA

Kura Oncology (KURA) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $10.60 +0.8% on the day +3.4% over 12 months 52-week range $7.40 – $13.59

Share price and insider trades

KURA closeInsider buyInsider sale
68101214NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $21,161 on 2026-05-18 · Teresa Brophy BairSold $23,616 on 2026-05-19 · Brian T. Powl, Kathleen FordSold $51,662 on 2026-08-21 · Brian T. PowlSold $109,800 on 2025-12-09 · Faheem HasnainSold $110,000 on 2026-05-21 · Brian T. PowlSold $224,463 on 2026-09-24 · Francis BurrowsSold $232,040 on 2025-12-18 · Francis BurrowsSold $305,135 on 2026-01-27 · Brian T. Powl, Francis Burrows, Kathleen Ford, Mollie Leoni, Teresa Brophy Bair, Thomas James DoyleSold $397,681 on 2026-08-19 · Teresa Brophy BairSold $498,818 on 2025-11-14 · Brian T. Powl, Kathleen Ford, Mollie Leoni, Teresa Brophy Bair, Thomas James DoyleSold $514,925 on 2026-09-29 · Brian T. Powl, Kathleen Ford, Mollie LeoniSold $519,422 on 2026-09-28 · Brian T. Powl, Kathleen Ford, Mollie Leoni, Teresa Brophy Bair, Thomas James DoyleSold $834,003 on 2026-06-18 · Mollie LeoniBought $1,112,000 on 2026-08-17 · Troy Edward WilsonBought $1,239,000 on 2026-08-24 · Troy Edward Wilson
Bought, 12 months$2.4M
Sold, 12 months$3.8M
Insiders buying1
Insiders selling7

Kura Oncology insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $2.4M and 7 sold $3.8M of KURA stock on the open market.

KURA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $841K sold (7 trades)Q4 2025Q1 2026: $305K sold (16 trades)Q1 2026Q2 2026: $989K sold (5 trades)Q2 2026Q3 2026: $2.4M bought (2 trades)$2.4MQ3 2026: $1.7M sold (12 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$2.4M2$1.7M12
Q2 2026—0$989K5
Q1 2026—0$305K16
Q4 2025—0$841K7

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$943MBiotechnology
Profit margin0.0%Revenue growth +36.5%
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit−$231KOn all tracked purchases -9.8%

Summary

Over the past 12 months, 1 Kura Oncology, Inc. insider reported open-market purchases totaling $2.4M, while 7 insiders reported sales totaling $3.8M. 18 of 40 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

KURA stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Sep 29SEC Mollie LeoniChief Medical Officer Sell Plan 28,802141,095 held (−17%) $10.75 $310K -1.4% —
Sep 29SEC Brian T. PowlChief Commercial Officer Sell Plan 15,430136,819 held (−10%) $10.75 $166K -1.4% —
Sep 29SEC Mollie LeoniChief Medical Officer Sell Plan 12,448169,897 held (−7%) $10.50 $131K +1.0% —
Sep 29SEC Brian T. PowlChief Commercial Officer Sell Plan 9,020160,249 held (−5%) $10.50 $95K +1.0% —
Sep 29SEC Teresa Brophy BairGeneral Counsel Sell Plan 8,442187,002 held (−4%) $10.50 $89K +1.0% —
Sep 29SEC Brian T. PowlChief Commercial Officer Sell Plan 8,000152,249 held (−5%) $10.56 $84K +0.4% —
Sep 29SEC Kathleen FordCOO Sell Plan 6,906146,654 held (−4%) $10.50 $73K +1.0% —
Sep 29SEC Thomas James DoyleSvp, Finance & Accounting Sell 4,607142,428 held (−3%) $10.50 $48K +1.0% —
Sep 29SEC Kathleen FordCOO Sell Plan 3,668142,986 held (−3%) $10.75 $39K -1.4% —
Sep 25SEC Francis BurrowsChief Scientific Officer Sell 20,72642,327 held (−33%) $10.83 $224K -2.1% —
Aug 24SEC Troy Edward WilsonCEO, President Buy 100,000479,194 held (+26%) $12.39 $1.2M -14.4% —
Aug 24SEC Brian T. PowlChief Commercial Officer Sell Plan 4,345169,269 held (−3%) $11.89 $52K -10.8% —
Aug 21SEC Teresa Brophy BairGeneral Counsel Sell Plan 31,487195,444 held (−14%) $12.63 $398K -16.1% —
Aug 17SEC Troy Edward WilsonCEO, President Buy 100,000379,194 held (+36%) $11.12 $1.1M -4.7% —
Jun 22SEC Mollie LeoniChief Medical Officer Sell Plan 84,929182,345 held (−32%) $9.82 $834K +7.9% —
May 22SEC Brian T. PowlChief Commercial Officer Sell Plan 10,000173,614 held (−5%) $11.00 $110K -3.6% —
May 20SEC Teresa Brophy BairGeneral Counsel Sell Plan 2,256226,931 held (−1%) $9.38 $21K +13.0% —
May 20SEC Kathleen FordCOO Sell Plan 2,257153,560 held (−1%) $9.08 $20K +16.7% —
May 20SEC Brian T. PowlChief Commercial Officer Sell Plan 339183,614 held (−0%) $9.21 $3K +15.1% —
Jan 27SEC Brian T. PowlChief Commercial Officer Sell 4,842184,847 held (−3%) $8.46 $41K +25.3% —
Jan 27SEC Teresa Brophy BairGeneral Counsel Sell 4,777226,931 held (−2%) $8.46 $40K +25.3% —
Jan 27SEC Teresa Brophy BairGeneral Counsel Sell 4,096234,043 held (−2%) $8.46 $35K +25.3% —
Jan 27SEC Mollie LeoniChief Medical Officer Sell 3,655271,799 held (−1%) $8.46 $31K +25.3% —
Jan 27SEC Teresa Brophy BairGeneral Counsel Sell 2,335231,708 held (−1%) $8.46 $20K +25.3% —
Jan 27SEC Mollie LeoniChief Medical Officer Sell 2,233269,566 held (−1%) $8.46 $19K +25.3% —
Jan 27SEC Thomas James DoyleSvp, Finance & Accounting Sell 2,226150,083 held (−1%) $8.46 $19K +25.3% —
Jan 27SEC Thomas James DoyleSvp, Finance & Accounting Sell 2,226146,048 held (−2%) $8.46 $19K +25.3% —
Jan 27SEC Kathleen FordCOO Sell 1,813153,560 held (−1%) $8.46 $15K +25.3% —
Jan 27SEC Brian T. PowlChief Commercial Officer Sell 1,572183,275 held (−1%) $8.46 $13K +25.3% —
Jan 27SEC Mollie LeoniChief Medical Officer Sell 1,341267,274 held (−0%) $8.46 $11K +25.3% —
Jan 27SEC Francis BurrowsChief Scientific Officer Sell 1,31132,424 held (−4%) $8.46 $11K +25.3% —
Jan 27SEC Thomas James DoyleSvp, Finance & Accounting Sell 1,114148,969 held (−1%) $8.46 $9K +25.3% —
Jan 27SEC Mollie LeoniChief Medical Officer Sell 951268,615 held (−0%) $8.46 $8K +25.3% —
Jan 27SEC Thomas James DoyleSvp, Finance & Accounting Sell 881145,167 held (−1%) $8.46 $7K +25.3% —
Jan 27SEC Thomas James DoyleSvp, Finance & Accounting Sell 695148,274 held (−0%) $8.46 $6K +25.3% —
Dec 19SEC Francis BurrowsChief Scientific Officer Sell 23,72633,735 held (−41%) $9.78 $232K +8.4% —
Dec 10SEC Faheem HasnainDirector Sell Plan 10,00023,983 held (−29%) $10.98 $110K -3.5% —
Nov 14SEC Mollie LeoniChief Medical Officer Sell 15,485225,454 held (−6%) $11.18 $173K -5.2% —
Nov 14SEC Brian T. PowlChief Commercial Officer Sell 8,887139,689 held (−6%) $11.18 $99K -5.2% —
Nov 14SEC Teresa Brophy BairGeneral Counsel Sell Plan 8,804188,139 held (−4%) $11.18 $98K -5.2% —
Nov 14SEC Kathleen FordCOO Sell Plan 6,902105,373 held (−6%) $11.18 $77K -5.2% —
Nov 14SEC Thomas James DoyleSvp, Finance & Accounting Sell 4,539130,257 held (−3%) $11.18 $51K -5.2% —

Insiders at Kura Oncology, Inc.

InsiderBoughtSoldLast filingScore
Troy Edward WilsonCEO, President $2.4M — Aug 24, 2026 —
Mollie LeoniChief Medical Officer — $1.5M Sep 29, 2026 —
Teresa Brophy BairGeneral Counsel — $701K Sep 29, 2026 —
Brian T. PowlChief Commercial Officer — $663K Sep 29, 2026 —
Francis BurrowsChief Scientific Officer — $468K Sep 25, 2026 —
Kathleen FordCOO — $225K Sep 29, 2026 —
Thomas James DoyleSvp, Finance & Accounting — $160K Sep 29, 2026 —
Faheem HasnainDirector — $110K Dec 10, 2025 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

KURA stock: common questions

Are Kura Oncology, Inc. insiders buying KURA stock?

In the past 12 months, 1 insiders reported open-market purchases of KURA worth $2.4M. The latest was CEO, President Troy Edward Wilson bought $1.2M of KURA at $12.39 — largest purchase by this insider in our records; raises the stake by 26%.

Are Kura Oncology, Inc. insiders selling KURA stock?

7 insiders reported sales worth $3.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is KURA's 52-week range?

Over the past year KURA has traded between $7.40 and $13.59. It last closed at $10.60 on Oct 9, 2026.